Acute myeloid leukemia and NK cells: two warriors confront each other

被引：33
作者：
Baragano Raneros, Aroa [1 ]
Lopez-Larrea, Carlos [1 ,2 ]
Suarez-Alvarez, Beatriz [1 ]
机构：
[1] Hosp Univ Cent Asturias, Inst Invest Sanitaria Principado Asturias ISPA, Translat Immunol Lab, Av Roma S-N, Oviedo 33011, Spain
[2] Hosp Univ Cent Asturias, Immunol Dept, Oviedo, Spain
来源：
ONCOIMMUNOLOGY | 2019年 / 8卷 / 02期
关键词：
Acute myeloid leukemia; natural killer cells; NKG2D; CAR-T; immunotherapy; immune checkpoints; NATURAL-KILLER-CELL; CHIMERIC ANTIGEN RECEPTORS; NKG2D LIGAND EXPRESSION; T-CELLS; ACTIVATING RECEPTORS; EFFECTOR FUNCTIONS; VALPROIC ACID; STEM-CELLS; ANTITUMOR; CANCER;
D O I：
10.1080/2162402X.2018.1539617
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Acute myeloid leukemia (AML) is a heterogeneous disease whose therapies currently show elevated toxicity and a high rate of relapse. Recently, the burgeoning of new anti-tumor therapeutic strategies aimed at enhancing the immune response has pushed natural killer cells (NKs) into the spotlight. These cells are powerful warriors that can bring about the lysis of tumor cells through their cytotoxic ability. However, tumor cells have developed strategies to evade recognition mediated by NKs. Here, we review the mechanisms triggered by AML cells and discuss the emerging immunotherapeutic strategies that potentiate the anti-tumor functions of NKs.
引用
收藏
页数：11
相关论文
共 75 条
  • [1] The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
    Arber, Daniel A.
    Orazi, Attilio
    Hasserjian, Robert
    Thiele, Jurgen
    Borowitz, Michael J.
    Le Beau, Michelle M.
    Bloomfield, Clara D.
    Cazzola, Mario
    Vardiman, James W.
    [J]. BLOOD, 2016, 127 (20) : 2391 - 2405
  • [2] Gene Mutations as Emerging Biomarkers and Therapeutic Targets for Relapsed Acute Myeloid Leukemia
    Aziz, Habsah
    Ping, Chow Y.
    Alias, Hamidah
    Ab Mutalib, Nurul-Syakima
    Jamal, Rahman
    [J]. FRONTIERS IN PHARMACOLOGY, 2017, 8
  • [3] Methylation of NKG2D ligands contributes to immune system evasion in acute myeloid leukemia
    Baragano Raneros, A.
    Martin-Palanco, V.
    Fernandez, A. F.
    Rodriguez, R. M.
    Fraga, M. F.
    Lopez-Larrea, C.
    Suarez-Alvarez, B.
    [J]. GENES AND IMMUNITY, 2015, 16 (01) : 71 - 82
  • [4] Increasing TIMP3 expression by hypomethylating agents diminishes soluble MICA, MICB and ULBP2 shedding in acute myeloid leukemia, facilitating NK cell-mediated immune recognition
    Baragano Raneros, Aroa
    Minguela Puras, Alfredo
    Rodriguez, Ramon M.
    Colado, Enrique
    Bernal, Teresa
    Anguita, Eduardo
    Vasco Mogorron, Adela
    Chaparro Gil, Alberto
    Vidal-Castineira, J. R.
    Marquez-Kisinousky, Leonardo
    Diaz Bulnes, Paula
    Martinez Marin, Amelia
    Garcia Garay, Maria Carmen
    Suarez-Alvarez, Beatriz
    Lopez-Larrea, Carlos
    [J]. ONCOTARGET, 2017, 8 (19) : 31959 - 31976
  • [5] Control of NK Cell Activation by Immune Checkpoint Molecules
    Beldi-Ferchiou, Asma
    Caillat-Zucman, Sophie
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2017, 18 (10)
  • [6] The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody
    Benson, Don M., Jr.
    Bakan, Courtney E.
    Mishra, Anjali
    Hofmeister, Craig C.
    Efebera, Yvonne
    Becknell, Brian
    Baiocchi, Robert A.
    Zhang, Jianying
    Yu, Jianhua
    Smith, Megan K.
    Greenfield, Carli N.
    Porcu, Pierluigi
    Devine, Steven M.
    Rotem-Yehudar, Rinat
    Lozanski, Gerard
    Byrd, John C.
    Caligiuri, Michael A.
    [J]. BLOOD, 2010, 116 (13) : 2286 - 2294
  • [7] In acute myeloid leukemia, B7-H1 (PD-L1) protection of blasts from cytotoxic T cells is induced by TLR ligands and interferon-gamma and can be reversed using MEK inhibitors
    Berthon, Celine
    Driss, Virginie
    Liu, Jizhong
    Kuranda, Klaudia
    Leleu, Xavier
    Jouy, Nathalie
    Hetuin, Dominique
    Quesnel, Bruno
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2010, 59 (12) : 1839 - 1849
  • [8] Improved outcome for AML patients over the years 2000-2014
    Bertoli, Sarah
    Tavitian, Suzanne
    Huynh, Anne
    Borel, Cecile
    Guenounou, Sarah
    Luquet, Isabelle
    Delabesse, Eric
    Sarry, Audrey
    Laurent, Guy
    Attal, Michel
    Huguet, Francoise
    Berard, Emilie
    Recher, Christian
    [J]. BLOOD CANCER JOURNAL, 2017, 7
  • [9] Expression patterns of NKG2A, KIR, and CD57 define a process of CD56dim NK-cell differentiation uncoupled from NK-cell education
    Bjorkstrom, Niklas K.
    Riese, Peggy
    Heuts, Frank
    Andersson, Sandra
    Fauriat, Cyril
    Ivarsson, Martin A.
    Bjorklund, Andreas T.
    Flodstrom-Tullberg, Malin
    Michaelsson, Jakob
    Rottenberg, Martin E.
    Guzman, Carlos A.
    Ljunggren, Hans-Gustaf
    Malmberg, Karl-Johan
    [J]. BLOOD, 2010, 116 (19) : 3853 - 3864
  • [10] Targeting FLT3 by chimeric antigen receptor T cells for the treatment of acute myeloid leukemia
    Chen, L.
    Mao, H.
    Zhang, J.
    Chu, J.
    Devine, S.
    Caligiuri, M. A.
    Yu, J.
    [J]. LEUKEMIA, 2017, 31 (08) : 1830 - 1834
12345678